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INTRODUCTION
Although considerable progress in technology and clinical research methods have led to advances in the approach to the diagnosis, prevention, and treatment of acute venous thromboembolism (VTE) [1] [2] [3] [4] [5] , the diagnosis is still often delayed and preventive methods are often ignored [6, 7] . The morbidity and mortality of VTE remain high. The primary goal in acute VTE is to prevent mortality by addressing acute pulmonary embolism and preventing thrombus extension and recurrent embolism. Anticoagulation is the standard of care in patients with acute VTE, but other options include thrombolytic therapy, inferior vena cava filter placement, and surgical embolectomy. Each approach has specific indications as well as advantages and disadvantages. Our focus will be thrombolytic therapy.
Thrombolytic agents activate plasminogen to form plasmin, which accelerates the lysis of thrombi and emboli. As a result, these agents have been used in different thrombotic disorders including acute myocardial infarction, acute deep venous thrombosis (DVT), and acute pulmonary embolism.
The efficacy, indications, contraindications, and adverse effects of thrombolytic therapy in acute pulmonary embolism and DVT are discussed here. In addition, the types of thrombolytic agents and regimens are reviewed.
Although there may be exceptions, generally only patients in whom the diagnosis of acute pulmonary embolism has been confirmed should be considered for thrombolytic therapy because the adverse effects of thrombolytic therapy can be devastating. For each patient, the indications and potential benefits must be carefully weighed against the risk of adverse events, and the patient's values and preferences should be considered. Bleeding risks are the primary concern and, although they may be obvious, such as in the setting of a recent
PATHOPHYSIOLOGY OF ACUTE PULMONARY EMBOLISM
The vast majority (95%) of acute pulmonary embolism originates from thrombi in the leg or pelvic veins, although emboli may arise from other sources such as the axillary subclavian system or the renal veins [8] . Death from acute pulmonary embolism is caused by right ventricular failure. When thrombosis propagates from the calf veins to the larger more proximal veins, or originates more proximally, the likelihood of embolization as well as the impact on the lungs increases. As the embolic burden increases, right ventricular afterload increases and there is right ventricular dilation and hypokinesis. When the clot burden reaches a critical threshold, the right ventricle (RV) is unable to generate enough force to achieve an adequate cardiac output and fails, resulting in hypotension and cardiac arrest. A crucial issue in acute pulmonary embolism is how to risk-stratify patients, that is, how we translate the status of the RV into meaningful treatment decisions.
RISK STRATIFICATION IN ACUTE PULMONARY EMBOLISM
Massive pulmonary embolism has been defined as acute pulmonary embolism accompanied by hemodynamic compromise, which has generally been defined as hypotension with a SBP less than 90 mmHg, persisting for at least 15 min. Such a definition is obviously imperfect, as stable patients with various illnesses (e.g., congestive heart failure) may run blood pressures in this range when clinically stable. The American College of Chest Physicians (ACCP) currently carries a grade 2C level of evidence recommendation in support of thrombolytic administration to hemodynamically unstable (massive pulmonary embolism) patients with acute pulmonary embolism in the absence of absolute contraindications [9 && ]. This represents a change in the recommendation from a grade 1B recommendation in 2008 without a change in the evidence base. Although most clinicians agree with considering this form of therapy, they are often reluctant. A summary of the ACCP recommendations for administration of thrombolytic therapy is outlined below.
Key recommendations on thrombolytic therapy in acute pulmonary embolism, abbreviated from the ACCP 2012 [the decision to use thrombolytics depends on the clinician's assessment of pulmonary embolism severity, prognosis, and bleeding risk; grade 1 denotes a strong recommendation and grade 2 denotes a weak recommendation ('suggestion'); level A would be based upon high-quality randomized trial data, whereas level B indicates moderatequality evidence, and level C low-quality or very low-quality evidence], are as follows:
(1) In patients with acute pulmonary embolism associated with hypotension (e.g., SBP <90 mmHg) without a high bleeding risk, we suggest systemically administered thrombolytic therapy (grade 2C). (2) In most patients with acute pulmonary embolism not associated with hypotension, we recommend against systemically administered thrombolytic therapy (grade 1C). (3) In selected patients with acute pulmonary embolism without hypotension and with a low bleeding risk in whom there appears to be a high risk of developing hypotension, we suggest administration of thrombolytic therapy (grade 2C). (4) When a thrombolytic agent is used, we suggest short infusion times (e.g., a 2-h infusion) (grade 2C). (5) In patients with acute pulmonary embolism when a thrombolytic agent is used, we suggest administration through a peripheral vein. Central administration is not deemed necessary (grade 2C). (6) In patients with acute pulmonary embolism associated with hypotension and who have contraindications to thrombolysis, or failed thrombolysis, if appropriate expertise and resources are available, we suggest catheter-assisted thrombus removal over no such intervention (grade 2C).
KEY POINTS
In the setting of acute massive pulmonary embolism, thrombolytic therapy should be strongly considered, in the absence of contraindications.
Thrombolytic therapy may also be considered in submassive pulmonary embolism; in this setting, other criteria may also be examined including biomarkers, oxygenation, and clot burden.
Intracranial bleeding is the most feared complication of thrombolytic therapy, and neurologic status should be closely monitored after administration.
Catheter-based techniques can be considered and, although they may be associated with less bleeding, expertise and proper facilities are required. (7) In patients with acute pulmonary embolism associated with hypotension, we suggest surgical pulmonary embolectomy over no such intervention if there are contraindications to thrombolysis, or if thrombolysis or catheterassisted embolectomy fails, provided surgical expertise and resources are available (grade 2C).
A more challenging dilemma lies with the patient who is not hemodynamically compromised per se, but in whom there appears to be a high risk of decompensation. Stable patients with an abnormal RV and normal blood pressure ('submassive pulmonary embolism') may fall into this category. In hemodynamically stable patients with right ventricular dysfunction, Konstantinides et al. [10] demonstrated that patients who received tissue-type plasminogen activator were significantly less likely to clinically deteriorate than those who received placebo (11 versus 25%), although there was no difference in all-cause mortality. However, treating physicians were allowed to break protocol and administer thrombolytics if they believed that a patient was doing poorly, and there was a high rate of rescue thrombolysis. A number of studies offer compelling arguments that right ventricular dysfunction is an important marker for mortality [11, 12] . In the International Cooperative Pulmonary Embolism Registry registry, the in-hospital mortality of patients with right ventricular dysfunction on echocardiography was 18%, although patients with shock were not analyzed separately [13] . The potential mortality benefit of thrombolytic therapy in pulmonary embolism patients with right ventricular dysfunction and preserved systemic arterial blood pressure should be carefully considered, although randomized trials to date have not offered clear proof. As noted subsequently, other factors may aid in the decision to proceed with such aggressive approaches. Extensive bilateral emboli are shown in Fig. 1a by computed tomographic angiography (CTA) in a normotensive patient. In Fig. 1b , the CTA reveals right ventricular enlargement in the same patient, that is, submassive pulmonary embolism.
It would be ideal to explore the impact of various 'degrees' of right ventricular enlargement and dysfunction. It is unlikely that mild right ventricular dysfunction would result in death in a pulmonary embolism patient in the absence of recurrent emboli; more extreme right ventricular dysfunction is more likely to.
Although the ECG has generally been deemed less useful than echocardiography in risk stratification, it may reveal T-wave inversion or a pseudoinfarction pattern (Qr) in the anterior precordial leads. This suggests right ventricular dilation and dysfunction, which can be integrated into risk stratification decisions [14] . Finally, recent data suggest that mortality due to acute pulmonary embolism is higher in the setting of residual DVT, so that evaluation of the legs as part of the risk stratification protocol in acute pulmonary embolism should be considered [15 & ]. High levels of brain natriuretic peptide (BNP), pro-BNP, and cardiac troponins (both T and I) have been associated with a greater risk of death in patients with pulmonary embolism [16, 17] . A meta-analysis of 1985 pulmonary embolism patients from 20 studies showed that any elevation in troponin level confers a five-fold increase in short-term mortality [18] . Troponin levels predict outcome not only for pulmonary embolism patients in shock but also for those who are hemodynamically stable at presentation. Again, lack of randomization and differing definitions for significant elevation of biomarkers prevent firm conclusions. The American Heart Association Scientific Statement published in March 2011 offers Thrombolytic therapy in acute pulmonary embolism Tapson an excellent literature review and presents a compelling rationale for risk stratification of acute pulmonary embolism patients [19 && ]. Factors to be considered for risk stratification are shown below. An algorithm outlining suggested approaches to acute pulmonary embolism with hypotension, or in the setting of submassive pulmonary embolism, is offered in Fig. 2 [19 
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& ], and is modified from the American Heart Association Scientific Statement [19 && ]. Factors to consider when risk-stratifying patients with acute pulmonary embolism are as follows:
(1) Vital signs (excessive tachycardia/tachypnea, hypotension; unstable hemodynamics is the clearest indication for thrombolytic therapy; it is controversial as to whether hypotension caused by pulmonary embolism in the absence of the need for pressors constitutes a clear indication for thrombolysis; the need for pressors mandates strong consideration for thrombolytics); (2) Echocardiography (right ventricular enlargement/hypokinesis);
(3) Biomarkers (troponin/BNP); (4) Oxygenation; (5) Clot burden (lung and legs); (6) Comorbid disease/cardiopulmonary reserve; (7) Bleeding risk.
CONTRAINDICATIONS TO SYSTEMIC THROMBOLYTIC THERAPY
The importance of the contraindication depends to an extent on the strength of the indication. As an example, a contraindication is of more concern if the indication for systemic thrombolytic therapy is right ventricular dyskinesis than if the indication is shock. The risks versus benefits should always be weighed on a case-by-case basis.
Contraindications to systemic thrombolytic therapy in acute pulmonary embolism include an intracranial neoplasm, recent (i.e., <2 months) intracranial surgery or trauma, active or recent internal bleeding during the prior 6 months, history of a hemorrhagic stroke, bleeding diathesis, severe uncontrolled hypertension (i.e., SBP >200 mmHg or DBP >110 mmHg), nonhemorrhagic stroke within the prior 2 months, surgery within the previous 10 days, and thrombocytopenia (i.e., <100 000 platelets/ml [21 & ]. Thrombolytic therapy may cause moderate bleeding in menstruating women, but it has not been associated with major hemorrhage. Therefore, menstruation is not a contraindication to thrombolytic therapy. As an alternative to thrombolytic therapy, catheter or surgical embolectomy may be performed if the necessary resources and expertise are available. The decision of whether to pursue one of these approaches should be based on local expertise.
SPECIFIC REGIMENS OF SYSTEMIC THROMBOLYTIC THERAPY
Once contraindications are considered, and the decision is made to proceed with systemic thrombolysis, it should be realized that no clear data indicate that one thrombolytic agent is superior to another, and each of the Food and Drug Administration-approved thrombolytic agents is administered at a fixed dose, making measurements of coagulation unnecessary during infusion. Specific regimens are shown in Table 1 . Tissue-type plasminogen activator (2-h infusion) is most commonly used. Shorter regimens and even bolus dosing may be favored in cases of unstable patients with massive pulmonary embolism. Following infusion of thrombolytics, if heparin has been discontinued, the activated partial thromboplastin time should be measured and repeated at 4-h intervals until it is less than twice the upper limit of normal. At that point, continuous intravenous unfractionated heparin should be administered without a loading bolus dose. Some clinicians elect to simply continue heparin through the thrombolytic infusion. No randomized studies have evaluated the risk/benefit of continuing heparin during the thrombolytic infusion. Newer agents such as tenecteplase have been studied in acute pulmonary embolism; they are not approved for this indication [22] .
COMPLICATIONS OF SYSTEMIC THROMBOLYTIC THERAPY
The primary complication of thrombolytic therapy is bleeding. Intracranial hemorrhage is the most devastating (and often fatal) complication of thrombolytic therapy and occurs in 1-3% of patients [23] . Invasive procedures should be minimized around the time of therapy to decrease the risk of bleeding. A vascular puncture above the inguinal ligament can lead to retroperitoneal hemorrhage that is often initially silent but may be life-threatening.
CATHETER-BASED APPROACHES TO ACUTE PULMONARY EMBOLISM
Thrombolytic therapy is generally administered by peripheral intravenous infusion. A number of intrapulmonary arterial/intraembolic approaches have been evaluated, including intraembolic thrombolytic delivery, suction, rheolytic and rotational devices, and ultrasound-enhanced thrombolysis [20 & , [24] [25] [26] [27] [28] [29] [30] [31] . As with systemic thrombolysis and surgical embolectomy, clinical trial data for percutaneous catheter intervention (with or without thrombolytics) for acute pulmonary embolism are insufficient to formulate strong recommendations. The potential for an aggressive approach, with perhaps a lower bleeding risk than systemic thrombolysis, makes these approaches attractive. Transport to an interventional radiology facility may be necessary, making the decision more complex in critically ill patients.
Presence of acute pulmonary embolism by CTA or ventilation perfusion scan should be proven prior to the procedure; alternatively, pulmonary arteriography can be performed in the interventional radiology laboratory in a patient with a high clinical suspicion for pulmonary embolism, who is compromised enough to consider treating aggressively. Hemodynamic and ECG monitoring should be undertaken. In patients with massive pulmonary embolism, the amount of contrast material should be reduced. Because most compromised patients have large proximal emboli, manual injection of 10-15 ml of contrast agent is generally sufficient to document emboli. Power injection of larger volumes is generally not necessary and may be dangerous in the setting of right ventricular failure.
Overall success rates range from 67 to 100% [20 & ], but studies suffer from significant potential reporting bias. At present, local expertise and familiarity with a particular device should guide the clinician when a catheter-based procedure appears indicated. ,32]. Arrhythmias may occur when advancing the catheter through the right heart. The most serious complication resulting from these catheter-directed procedures is perforation or dissection of a pulmonary artery, causing massive pulmonary hemorrhage and immediate death. The risk of perforation increases with smaller vessels [33] . Other serious complications include pericardial tamponade. To minimize the risk of perforation or dissection, embolectomy procedures should only be performed in the main and lobar pulmonary artery branches and not attempted in smaller vessels.
Device-related complications include hemorrhage and mechanical hemolysis. Acute pancreatitis has been reported due to mechanical hemolysis [34] .
CONCLUSION
Thrombolytic therapy was first studied for the treatment of acute pulmonary embolism more than 40 years ago (urokinase pulmonary embolism trial). This therapy should be strongly considered in massive pulmonary embolism, although contraindications must be scrutinized. Although tremendous experience has been acquired, more randomized trials are needed, particularly in the area of submassive pulmonary embolism, examining the benefit of thrombolytics in right ventricular dysfunction. A clinician faced with a patient with acute pulmonary embolism should consider risk stratification based upon echocardiography. Biomarkers such as troponin, extent of clot burden, and oxygenation should all be considered. Potential contraindications to thrombolytics must be reviewed and systemic or catheter-based thrombolytics can be considered. The large ongoing European Pulmonary Embolism Thrombolysis study may offer more insight [35 && ] into treatment of submassive pulmonary embolism. The role of extent of clot burden in the lung and legs and the importance of biomarkers and severe hypoxemia in determining the need for this aggressive therapy must also be sorted out.
